The term peritoneal sclerosis can be applied to a vast range of peritoneal alterations. At one end of the range we have the slight peritoneal sclerosis constantly associated with peritoneal dialysis, which may be defined as simple sclerosis. Its clinical impact is slight.
The role of glucose in determining peritoneal sclerosis is supported by morphological studies and therefore backed by much biochemical and immunological data.
Di PaoloN., SacchiG.Atlas of peritoneal histology. Perit Dial Int2000; (suppl 3): S20.
4.
GarosiG., Di PaoloN.Peritoneal sclerosis: One ot two nosological entities?Semin Dial2000; 13: 297–308.
5.
MortierS., FaictD., SchalkwijkC.G., LamiereN.H., De VrieseA.S.Long term exposure to new peritoneal dialysis solutions: Effect on the peritoneal membrane. Kidney Int2004; 66: 1257–65.
6.
WilliamsJ.D., CraigK.J., TopleyN., Von RuhlandC., FallonM., NewmanG.R., MacKenzieR.K., WilliamsG.T.Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol2002; 13: 470–9.
7.
SelgasR., Fernanzed-ReyesM.J., BosqueE., BajoM.A., BorregoF., JimenezC., Del PesoG., De AlvaroF.Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis1994; 23: 64–73.
8.
Di PaoloN., SacchiG.Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangiopathy. Perit Dial Int1989; 9: 41–5.
9.
GotloibL., BarsellaP., ShostakA.Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum. Perit Dial Bull1985; 5: 212–5.
10.
Di PaoloN., GarosiG., TraversariL.Mesothelial biocompatibility of peritoneal dialysis solution. Perit Dial Int1993; 13(suppl): S109–12.
11.
GotloibL., WajsbrotV., ShostakA.Ecology of the peritoneum: A substantial role for the osmotic agents resulting in apoptosis of mesothelial cells. Contrib Nephrol2003; 140: 10–17.
12.
GarosiG., Di PaoloN.Inflammation and gross vascular alterations are characteristic histological features of sclerosing peritonitis. Perit Dial Int2001; 21: 417–20.
13.
Di PaoloN., SacchiG.Anatomy and physiology of the peritoneal membrane. Contrib Nephrol1990; 84: 10–26.
14.
NaikiY., MaedaY., MatsuoK., YonekawaS., SakaguchiM., IwamotoI., HasegawaH., KanamaruA.Involvement of TGF-beta signal for peritoneal sclerosing in continuous ambulatory peritoneal dialysis. J Nephrol2003; 16: 95–102.
15.
OgataS., YoriokaN., KiribayashiK., NaitoT., KuratsuneM., NishidaY.Viability of, and basic fibroblast growth factor secretion by, human peritoneal mesothelial cells cultured with various components of peritoneal dialysis fluid. Adv Perit Dial2003; 19: 2–5.
16.
De VrieseA.S., FlyvbjergA., MortierS., TiltonR.G., LameireN.H.Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol2003; 14: 2109–18.
17.
Yanez-MoM., Lara-PezziE., SelgasR., Ramirez-HuescaM.Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med2003; 348: 403–13.
18.
HaH., ChaM.K., ChoiH.N., LeeH.B.Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int2002; 22: 171–7.
19.
GillerotG., DevuystO.Molecular mechanisms modifying the peritoneal membrane exposed to peritoneal dialysis. Clin Nephrol2003; 60: 1–6.
20.
MortierS., FaictD., SchalkwijkC.G., LameireN.H., De VrieseA.S.Long term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int2004; 66: 1257–65.
PlumJ., HermannS., FusshollerA., SchoenickeG., DonnerA., RohrbornA., GrabenseeB.Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int2001; 78(suppl): S42–7.
25.
DevuystO., TopleyN., WilliamsJ.D.Morphological and functional changes in the dialysed peritoneal cavity: Impact of more biocompatible solutions. Nephrol Dial Transplant2002; 17(suppl 3): S12–5.
